Investigators presented data about 3 global phase 3 trials of roxadustat at a national nephrology meeting Thursday to a standing-room only crowd, but the information they are really waiting to hear will have to wait until early Friday afternoon.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,